Intellia Therapeutics Inc.

30/07/2024 | Press release | Distributed by Public on 30/07/2024 21:08

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA 3001 for the Treatment of Alpha 1 Antitrypsin Deficiency

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.